[A 2004 update on treatment and prophylaxis of opportunistic infections in the course of HIV disease. Part 1: Pneumocystosis and protozoiasis].
Remarkable progress has been made in antiretroviral therapeutics, as well as in the prophylaxis and treatment of opportunistic infections, since the beginning of the AIDS epidemic. The patient's life expectancy and quality of life have consequently improved, thanks to better management of opportunistic diseases. The introduction of protease inhibitors-containing regimen (i.e. Highly Active Antiretroviral Therapy or HAART), since 1996, has drastically reduced the incidence of opportunistic infections by restoring immunity. The large panel of antiretroviral drugs responsible for frequent sustained viral and immune responses has thus allowed a new definition of guidelines for the prophylaxis and treatment of opportunistic infections. A better use of prophylactic drugs should help reduce the risk of drug-related toxicity and pharmaceutical interactions. It should also decrease the cost of HIV management and eventually increase compliance to treatment and quality of life.
Lacombe
K
K
Service des maladies infectieuses et tropicales, hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. karine.lacombe@sat.ap-hop-paris.fr
Girard
P M
PM
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology / Q000469:parasitology / Q000517:prevention & control*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D006801:Humans; D010349:Patient Compliance; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000517:prevention & control*; D011528:Protozoan Infections / Q000188:drug therapy* / Q000517:prevention & control*; D011788:Quality of Life
D044966:Anti-Retroviral Agents